# Orchid Pharma (NSE: ORCHPHARMA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ORCHPHARMA · Pivot · prices to 21 Oct 2026

Orchid Pharma (NSE: ORCHPHARMA) closed at ₹896.90 on 21 Oct 2026. With a market capitalisation of ₹4,519 Cr, it ranks 834th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 217.8× trailing earnings, against a return on equity of 1.6% in FY26. Over the past year the share price has risen 19.3%. Its 52-week range is ₹480.00 (30 Mar 2026) to ₹1,143.50 (22 Sep 2026); the last close is 21.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹238 Cr (+0.1% year on year) and net profit ₹23 Cr (+19.1%), on a consolidated basis. Promoters held 69.84% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹896.90 |
| Market cap | ₹4,519 Cr |
| P/E (trailing) | 217.8 |
| ROE | 1.6% (FY26) |
| ROCE | 2.5% (FY26) |
| Debt to equity | 0.28 |
| 52-week high | ₹1,143.50 (22 Sep 2026) |
| 52-week low | ₹480.00 (30 Mar 2026) |
| 1-year return | +19.3% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹238 Cr | +0.1% | ₹23 Cr | +19.1% | ₹4.69 |
| Q3 FY26 | ₹207 Cr | −4.6% | −₹12 Cr | −154.1% | −₹2.49 |
| Q2 FY26 | ₹194 Cr | −13.1% | −₹3 Cr | −112.9% | −₹1.13 |
| Q1 FY26 | ₹173 Cr | −29.2% | ₹14 Cr | −51.5% | ₹2.94 |
| Q4 FY25 | ₹237 Cr | +9.4% | ₹19 Cr | −42.9% | ₹4.40 |
| Q3 FY25 | ₹217 Cr | −1.5% | ₹22 Cr | −25.6% | ₹4.10 |
| Q2 FY25 | ₹223 Cr | +12.0% | ₹26 Cr | +29.4% | ₹5.37 |
| Q1 FY25 | ₹244 Cr | +33.6% | ₹28 Cr | +162.2% | ₹5.79 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹922 Cr | ₹96 Cr |
| FY24 | ₹819 Cr | ₹95 Cr |
| FY23 | ₹666 Cr | ₹48 Cr |
| FY22 | ₹560 Cr | ₹2 Cr |
| FY21 | ₹450 Cr | −₹117 Cr |
| FY20 | ₹508 Cr | −₹131 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 69.84%
- Foreign institutions: 0.81%
- Domestic institutions: 20.75%
- Non-institutions: 8.61%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Novartis India](https://app.pivotnow.in/stock/NOVARTIND) | ₹1,919.80 | ₹4,740 Cr | 50.9 | — |
| [Zota Health Care](https://app.pivotnow.in/stock/ZOTA) | ₹1,361.00 | ₹4,713 Cr | — | — |
| [RPG Life Sciences](https://app.pivotnow.in/stock/RPGLIFE) | ₹2,849.00 | ₹4,712 Cr | 40.9 | — |
| [Jeena Sikho Lifecare](https://app.pivotnow.in/stock/JSLL) | ₹367.20 | ₹4,564 Cr | 20.7 | — |
| [Gufic Biosciences](https://app.pivotnow.in/stock/GUFICBIO) | ₹404.00 | ₹4,051 Cr | 63.1 | — |
| [SMS Pharmaceuticals](https://app.pivotnow.in/stock/SMSPHARMA) | ₹432.55 | ₹4,051 Cr | 38.8 | — |

## Questions and answers

### What is the share price of Orchid Pharma today?

Orchid Pharma (NSE: ORCHPHARMA) last closed at ₹896.90 on 21 Oct 2026. Its 52-week high is ₹1,143.50 and its 52-week low is ₹480.00.

### What is the market cap of Orchid Pharma?

Orchid Pharma's market capitalisation is ₹4,519 Cr (₹4,519 Cr) at the 19 Oct 2026 close, ranking 834th among the NSE companies Pivot tracks.

### What is the P/E ratio of Orchid Pharma?

Orchid Pharma trades at a trailing P/E of 217.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 40.9.

### What is the ROE and ROCE of Orchid Pharma?

Return on equity was 1.6% in FY26 and return on capital employed was 2.5% in FY26 (consolidated figures).

### Is Orchid Pharma a debt-free company?

No. Orchid Pharma's debt-to-equity ratio was 0.28 in FY26, with total debt of ₹328 Cr.

### What were Orchid Pharma's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Orchid Pharma reported revenue of ₹238 Cr, +0.1% year on year, and net profit of ₹23 Cr, +19.1% year on year.

### How has Orchid Pharma stock performed over the last year?

Orchid Pharma's share price has risen 19.3% over the past year, −14.9% over three months and −7.5% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Orchid Pharma?

As of 30 Jun 2026: promoters 69.84%, foreign institutions 0.81%, domestic institutions 20.75%, non-institutions 8.61%.

### Who are Orchid Pharma's competitors?

The listed Pharma & Healthcare companies closest to Orchid Pharma by market cap are Novartis India, Zota Health Care, RPG Life Sciences, Jeena Sikho Lifecare, Gufic Biosciences and SMS Pharmaceuticals.

### Is Orchid Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Orchid Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ORCHPHARMA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.